Literature DB >> 21381897

Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes.

Cliff Chen1, Yong-Hae Han, Zheng Yang, A David Rodrigues.   

Abstract

The purpose of this study was to assess the impact of interferon-α2b (IFN-α2b) on the expression of various drug-metabolizing enzymes and transporters in freshly prepared co-cultures (parenchymal and non-parenchymal cells) of human primary hepatocytes. At therapeutically relevant concentrations (from 1000 to 3000 IU/mL), IFN-α2b up-regulated STAT1 (signal transducer and activator of transcription factor 1) mRNA expression. Conversely, three cytochrome P450s (CYP1A2, CYP2B6, CYP2E1), a UDP-glucuronosyltransferase (UGT2B7), a sulphotransferase (SULT1A1) and organic anion transporter (OAT2) were significantly down-regulated (~50%; P < 0.05). Western blot analysis of CYP1A2, UGT2B7 and OAT2 protein supported the mRNA data. Two peroxisome proliferator activator receptor alpha (PPARα)-controlled genes (pyruvate dehydrogenase kinase 4 and adipose differentiation-related protein), CYP3A4 and multidrug resistance-associated protein 2 were significantly up-regulated (up to 223%; P < 0.05). On the other hand, SULT2A1, carboxylesterase 2, organic anion transporting peptide (OATP1B1, OATP1B3, OATP2B1), organic cation transporter 1, P-glycoprotein and breast cancer resistance protein mRNA expression was not significantly affected. Western blot analysis of CYP3A4 supported the mRNA data also. The present results demonstrated complex interactions between IFN-α2b and hepatocytes and the observed down-regulation of CYP1A2, OAT2 and UGT2B7 is consistent with reports of drug interactions between IFN-α2b and drugs such as theophylline, clozapine and gemfibrozil.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21381897     DOI: 10.3109/00498254.2011.560971

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.

Authors:  Atsushi Kudo; Kaoru Mogushi; Tadatoshi Takayama; Satoshi Matsumura; Daisuke Ban; Takumi Irie; Takanori Ochiai; Noriaki Nakamura; Hiroshi Tanaka; Naohiko Anzai; Michiie Sakamoto; Shinji Tanaka; Shigeki Arii
Journal:  J Gastroenterol       Date:  2013-03-30       Impact factor: 7.527

2.  Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity.

Authors:  Barbara J Brennan; Zhi-Xin Xu; Joseph F Grippo
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

Authors:  Luciene Terezina de Lima; Douglas Vivona; Carolina Tosin Bueno; Rosario D C Hirata; Mario H Hirata; André D Luchessi; Fabíola Attié de Castro; Maria de Lourdes F Chauffaille; Maria A Zanichelli; Carlos S Chiattone; Vania T M Hungria; Elvira M Guerra-Shinohara
Journal:  Med Oncol       Date:  2014-01-29       Impact factor: 3.064

4.  The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D).

Authors:  C L Raison; A H Miller
Journal:  Mol Psychiatry       Date:  2012-01-31       Impact factor: 15.992

5.  Immunological response as a source to variability in drug metabolism and transport.

Authors:  Hege Christensen; Monica Hermann
Journal:  Front Pharmacol       Date:  2012-02-10       Impact factor: 5.810

6.  Effects of monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, and interferon-α2a on P450 enzymes in human hepatocytes in vitro.

Authors:  Maciej Czerwiński; Krystal Gilligan; Kevin Westland; Brian W Ogilvie
Journal:  Pharmacol Res Perspect       Date:  2019-12-10

Review 7.  Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Authors:  Devendra Kumar; Neerja Trivedi
Journal:  Biomed Pharmacother       Date:  2021-04-27       Impact factor: 7.419

8.  Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes.

Authors:  Dirk Theile; Lelia Wagner; Cindy Bay; Walter Emil Haefeli; Johanna Weiss
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.